- Home
- JRS vs DSGN Comparison
JRS vs DSGN Comparison
Compare JRS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- DSGN
- Stock Information
- Founded
- JRS 2001
- DSGN 2017
- Country
- JRS United States
- DSGN United States
- Employees
- JRS N/A
- DSGN N/A
- Industry
- JRS Finance/Investors Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- DSGN Health Care
- Exchange
- JRS Nasdaq
- DSGN Nasdaq
- Market Cap
- JRS 224.5M
- DSGN 208.9M
- IPO Year
- JRS N/A
- DSGN 2021
- Fundamental
- Price
- JRS $7.58
- DSGN $3.82
- Analyst Decision
- JRS
- DSGN Hold
- Analyst Count
- JRS 0
- DSGN 1
- Target Price
- JRS N/A
- DSGN $4.00
- AVG Volume (30 Days)
- JRS 86.6K
- DSGN 94.3K
- Earning Date
- JRS 01-01-0001
- DSGN 08-12-2025
- Dividend Yield
- JRS 8.87%
- DSGN N/A
- EPS Growth
- JRS N/A
- DSGN N/A
- EPS
- JRS N/A
- DSGN N/A
- Revenue
- JRS N/A
- DSGN N/A
- Revenue This Year
- JRS N/A
- DSGN N/A
- Revenue Next Year
- JRS N/A
- DSGN N/A
- P/E Ratio
- JRS N/A
- DSGN N/A
- Revenue Growth
- JRS N/A
- DSGN N/A
- 52 Week Low
- JRS $5.95
- DSGN $2.60
- 52 Week High
- JRS $8.00
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- JRS 34.42
- DSGN 45.61
- Support Level
- JRS $7.80
- DSGN $3.76
- Resistance Level
- JRS $7.88
- DSGN $4.19
- Average True Range (ATR)
- JRS 0.12
- DSGN 0.22
- MACD
- JRS -0.03
- DSGN -0.03
- Stochastic Oscillator
- JRS 9.30
- DSGN 8.82
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.